BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials
Clinical Trials · 2023-10 · 20 (5) · 486-496
DOI: 10.1177/17407745231176445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, online erschienen am 14.06.2023. Verfasst von Liyun Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Research Design. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.
Methods
The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.
Results
The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.
Conclusion
The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Fangrong Yan, Ying Yuan
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Jiang, L., Thall, P. F., Yan, F., Kopetz, S., & Yuan, Y. (2023). BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials, 20(5), 486-496. https://doi.org/10.1177/17407745231176445
Vancouver
Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials. 2023;20(5):486-496. doi:10.1177/17407745231176445
BibTeX
@article{Jiang2023,
author = {Jiang, Liyun and Thall, Peter F and Yan, Fangrong and Kopetz, Scott and Yuan, Ying},
title = {BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials},
journal = {Clinical Trials},
year = {2023},
volume = {20},
number = {5},
pages = {486--496},
doi = {10.1177/17407745231176445}
}
EUVIMED